Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Drugs in the Pipeline"'
Autor:
Alexander Burashnikov
Publikováno v:
Journal of Cardiovascular Pharmacology
Antiarrhythmic drugs remain the mainstay therapy for patients with atrial fibrillation (AF). A major disadvantage of the currently available anti-AF agents is the risk of induction of ventricular proarrhythmias. Aiming to reduce this risk, several at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35d89e2be2b5324f9f0fc7aa4b0963d5
http://europepmc.org/articles/PMC7641178
http://europepmc.org/articles/PMC7641178
Autor:
Alessandra Vecchié, Edoardo Bressi, Benjamin W. Van Tassell, Salvatore Carbone, George F. Wohlford, Antonio Abbate, Amr Marawan, Dinesh Kadariya, Juan Guido Chiabrando, Hayley Billingsley, Megan Dell, Ai-Chen Ho, Virginia L. Mihalick, Jeremy Turlington, Cory R. Trankle, Roshanak Markley, Aldo Bonaventura, Justin M. Canada, Georgia K. Thomas
Publikováno v:
Journal of Cardiovascular Pharmacology
Supplemental Digital Content is Available in the Text.
The NLRP3 inflammasome has been implicated in the development and progression of heart failure. The aim of this study was to determine the safety of an oral inhibitor of the NLRP3 inflammaso
The NLRP3 inflammasome has been implicated in the development and progression of heart failure. The aim of this study was to determine the safety of an oral inhibitor of the NLRP3 inflammaso
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b08f78322497e24d9445f4bf3ba07698
https://pubmed.ncbi.nlm.nih.gov/33165145
https://pubmed.ncbi.nlm.nih.gov/33165145
Autor:
Gabriella Malfatto, Matti Kivikko, Veli-Pekka Harjola, Johann Altenberger, Finn Gustafsson, Piero Pollesello, Kristjan Karason, Zoltán Papp, Detlef Kindgen-Milles, Carsten Tschöpe, John Parissis, Gerhard Pölzl
Publikováno v:
Journal of Cardiovascular Pharmacology
Altenberger, J, Gustafsson, F, Harjola, V-P, Karason, K, Kindgen-Milles, D, Kivikko, M, Malfatto, G, Papp, Z, Parissis, J, Pollesello, P, Pölzl, G & Tschöpe, C 2018, ' Levosimendan in Acute and Advanced Heart Failure : An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications ', Journal of Cardiovascular Pharmacology, vol. 71, no. 3, pp. 129-136 . https://doi.org/10.1097/FJC.0000000000000533
Altenberger, J, Gustafsson, F, Harjola, V-P, Karason, K, Kindgen-Milles, D, Kivikko, M, Malfatto, G, Papp, Z, Parissis, J, Pollesello, P, Pölzl, G & Tschöpe, C 2018, ' Levosimendan in Acute and Advanced Heart Failure : An Appraisal of the Clinical Database and Evaluation of Its Therapeutic Applications ', Journal of Cardiovascular Pharmacology, vol. 71, no. 3, pp. 129-136 . https://doi.org/10.1097/FJC.0000000000000533
The use of inotropes for correcting hemodynamic dysfunction in patients with congestive heart failure has been described over many decades. However, negative or insufficient data have been collected regarding the effects of cardiac glycosides, catech
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc67f375e178ff6586db68b5bb287804
http://hdl.handle.net/10138/234833
http://hdl.handle.net/10138/234833
Autor:
Stefaan Bouchez, Matti Kivikko, Fabio Guarracino, Piero Pollesello, Angela Rajek, Matthias Heringlake, Vladimir V. Lomivorotov, Bernard Cholley, Dominique Bettex
Publikováno v:
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
Journal of Cardiovascular Pharmacology
Journal of Cardiovascular Pharmacology
Levosimendan is a calcium sensitizer and ATP-dependent potassium channel opener which exerts sustained hemodynamic, symptomatic and organ-protective effects. It is registered for the treatment of acute heart failure, and when inotropic support is con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bac79205967221c87c2a700353f5aed9
https://www.zora.uzh.ch/id/eprint/142247/
https://www.zora.uzh.ch/id/eprint/142247/
Publikováno v:
Journal of Cardiovascular Pharmacology
Scopus-Elsevier
Scopus-Elsevier
Acute heart failure (AHF) emerges as a major and growing epidemiological concern with high morbidity and mortality rates. Current therapies in patients with acute heart failure rely on different strategies. Patients with hypotension, hypoperfusion, o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad8fa0e1df66d7acc73b81bfa07bfe68
https://doi.org/10.1097/fjc.0000000000000113
https://doi.org/10.1097/fjc.0000000000000113